Clinical Evaluation of Ampicillin/Sulbactam in Patients with Ventilator Associated Pneumonia

Phase 2

Recruiting

Conditions: Ventilator associated Pneumonia.
Ventilator associated pneumonia
J95.851

Registration Number: IRCT20180802040665N2

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

Patients aged more than 18 years old
VAP diagnosis according to the IDSA guidelines (new pulmonary infiltration with clinical symptoms including fever, purulent secretions, leukocytosis, and decreased blood oxygen levels occurring after 48 hours of mechanical ventilation).
Sign the informed consent form
Reporting of resistance Acinetobacter in the pulmonary secretion (concurrent resistance to aminoglycosides, fluoroquinolones, cephalosporins, penicillins and carbapenems).

Exclusion Criteria

Breastfeeding and pregnant patients.
Patients who have an infection of another source other than the infection caused by the mechanical ventilation device.
Obese patients with body mass index more than 35.
Patients who have a history of allergy to medicines in the therapeutic regimen.
Patients with underlying lung diseases.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The percentage of patients who recovered without changing their antibiotic regimen during the study. Timepoint: 10 days after the start of the study. Method of measurement: Relief of fever, reduction of purulent secretions and no need for vasopressor for at least 48 hours.;Mortality rate. Timepoint: 10 days after the start of the study. Method of measurement: Evaluation of patients' medical records.

Secondary Outcome Measures

Name	Time	Method
The percentage of patients who manage to be weaned from mechanical ventilation or tolerate spontaneous breathing mode. Timepoint: 10 days after the start of the study. Method of measurement: Evaluation of patients' ventilators.;Length of stay in ICU. Timepoint: 10 days after the start of the study. Method of measurement: Evaluation of patients' medical records.;Percentage of patients who develop the adverse drug reactions. Timepoint: Daily up to 10 days. Method of measurement: Examination of patients.